Switch to:

CRISPR Therapeutics AG Change In Receivables

: $0.3 Mil (TTM As of Jun. 2020)
View and export this data going back to 2016. Start your Free Trial

CRISPR Therapeutics AG's change in receivables for the quarter that ended in Jun. 2020 was $25.1 Mil. It means CRISPR Therapeutics AG's Accounts Receivable increased by $25.1 Mil from Mar. 2020 to Jun. 2020 .

CRISPR Therapeutics AG's change in receivables for the fiscal year that ended in Dec. 2019 was $-0.0 Mil. It means CRISPR Therapeutics AG's Accounts Receivable declined by $0.0 Mil from Dec. 2018 to Dec. 2019 .

CRISPR Therapeutics AG's Accounts Receivable for the quarter that ended in Jun. 2020 was $0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CRISPR Therapeutics AG's Days Sales Outstanding for the three months ended in Jun. 2020 was 68.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CRISPR Therapeutics AG's liquidation value for the three months ended in Jun. 2020 was $809.2 Mil.


CRISPR Therapeutics AG Change In Receivables Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

CRISPR Therapeutics AG Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Change In Receivables Premium Member Only -0.34 -2.82 0.53 2.54 -0.01

CRISPR Therapeutics AG Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Change In Receivables Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.28 -0.06 -25.02 25.08

CRISPR Therapeutics AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2020 was 0.282 (Sep. 2019 ) + -0.06 (Dec. 2019 ) + -25.018 (Mar. 2020 ) + 25.084 (Jun. 2020 ) = $0.3 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


CRISPR Therapeutics AG  (NAS:CRSP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CRISPR Therapeutics AG's Days Sales Outstanding for the quarter that ended in Jun. 2020 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.033/0.044*91
=68.44

2. In Ben Graham's calculation of liquidation value, CRISPR Therapeutics AG's accounts receivable are only considered to be worth 75% of book value:

CRISPR Therapeutics AG's liquidation value for the quarter that ended in Jun. 2020 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=945.068-135.862+0.75 * 0.033+0.5 * 0
=809.2

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


CRISPR Therapeutics AG Change In Receivables Related Terms


CRISPR Therapeutics AG Change In Receivables Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)